Moderna CEO on Earnings, Flu Shots and Skin Cancer Trials

Moderna's ability to pivot and find growth opportunities outside the US is crucial for its long-term viability, especially as the demand for COVID-19 vaccines stabilizes. The anticipated skin cancer trial results could not only enhance the company's portfolio but also position it as a significant player in oncology, a field ripe for innovation. However, the company's past struggles with political and market pressures will require careful navigation as it seeks to establish a sustainable growth trajectory.